145 related articles for article (PubMed ID: 35159092)
41. Early recovery of the platelet count after decitabine-based induction chemotherapy is a prognostic marker of superior response in elderly patients with newly diagnosed acute myeloid leukaemia.
Huang J; Zhao H; Hong M; Zhu H; Zhu Y; Lian Y; Li S; Li J; Qian S
BMC Cancer; 2018 Dec; 18(1):1269. PubMed ID: 30567513
[TBL] [Abstract][Full Text] [Related]
42. Survival outcomes of hypomethylating agents maintenance therapy in new diagnosed AML patients: Real experience data.
Karakus V; Maral S; Kaya E; Gemici A; Dere Y; Sevindik OG
North Clin Istanb; 2022; 9(4):331-336. PubMed ID: 36276561
[TBL] [Abstract][Full Text] [Related]
43. Preclinical and phase I results of decitabine in combination with midostaurin (PKC412) for newly diagnosed elderly or relapsed/refractory adult patients with acute myeloid leukemia.
Williams CB; Kambhampati S; Fiskus W; Wick J; Dutreix C; Ganguly S; Aljitawi O; Reyes R; Fleming A; Abhyankar S; Bhalla KN; McGuirk JP
Pharmacotherapy; 2013 Dec; 33(12):1341-52. PubMed ID: 23798029
[TBL] [Abstract][Full Text] [Related]
44. Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome.
Pusic I; Choi J; Fiala MA; Gao F; Holt M; Cashen AF; Vij R; Abboud CN; Stockerl-Goldstein KE; Jacoby MA; Uy GL; Westervelt P; DiPersio JF
Biol Blood Marrow Transplant; 2015 Oct; 21(10):1761-9. PubMed ID: 26055299
[TBL] [Abstract][Full Text] [Related]
45. Epigenetic priming with decitabine followed by low dose idarubicin and cytarabine in acute myeloid leukemia evolving from myelodysplastic syndromes and higher-risk myelodysplastic syndromes: a prospective multicenter single-arm trial.
Zhou X; Mei C; Zhang J; Lu Y; Lan J; Lin S; Zhang Y; Kuang Y; Ren Y; Ma L; Wei J; Ye L; Xu W; Li K; Lu C; Jin J; Tong H
Hematol Oncol; 2020 Oct; 38(4):531-540. PubMed ID: 32469434
[TBL] [Abstract][Full Text] [Related]
46. Intensive chemotherapy vs. hypomethylating agents in older adults with newly diagnosed high-risk acute myeloid leukemia: A single center experience.
Vachhani P; Al Yacoub R; Miller A; Zhang F; Cronin TL; Ontiveros EP; Thompson JE; Griffiths EA; Wang ES
Leuk Res; 2018 Dec; 75():29-35. PubMed ID: 30445237
[TBL] [Abstract][Full Text] [Related]
47. Ten-day decitabine as initial therapy for newly diagnosed patients with acute myeloid leukemia unfit for intensive chemotherapy.
Bhatnagar B; Duong VH; Gourdin TS; Tidwell ML; Chen C; Ning Y; Emadi A; Sausville EA; Baer MR
Leuk Lymphoma; 2014 Jul; 55(7):1533-7. PubMed ID: 24144313
[TBL] [Abstract][Full Text] [Related]
48. [Clinical observation of decitabine-treating patients with myelodysplastic syndrome and acute myeloid leukemia].
Yang H; Zhu HY; Jiang MM; Wang QS; Han XP; Huang WR; Jing Y; Wang SH; Zhang SS; Mei JH; Yu L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Feb; 21(1):121-5. PubMed ID: 23484704
[TBL] [Abstract][Full Text] [Related]
49. Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance).
Roboz GJ; Mandrekar SJ; Desai P; Laumann K; Walker AR; Wang ES; Kolitz JE; Powell BL; Attar EC; Stock W; Bloomfield CD; Kohlschmidt J; Mrózek K; Hassane DC; Garraway L; Jané-Valbuena J; Baltay M; Tracy A; Marcucci G; Stone RM; Larson RA
Blood Adv; 2018 Dec; 2(24):3608-3617. PubMed ID: 30567725
[TBL] [Abstract][Full Text] [Related]
50. Decitabine: a review of its use in older patients with acute myeloid leukaemia.
Curran MP
Drugs Aging; 2013 Jun; 30(6):447-58. PubMed ID: 23580320
[TBL] [Abstract][Full Text] [Related]
51. Indirect comparison of azacitidine and decitabine for the therapy of elderly patients with acute myeloid leukemia: a systematic review and network meta-analysis.
Wen B; You W; Yang S; Du X
Exp Hematol Oncol; 2020; 9():3. PubMed ID: 32190414
[TBL] [Abstract][Full Text] [Related]
52. Decitabine Compared With Conventional Regimens in Older Patients With Acute Myeloid Leukemia: A Meta-Analysis.
Bian MR; Yang HS; Lin GQ; Wan Y; Wang L; Si YJ; Zhang XX; Wang M; Zhou H; Zhao GS; Zhang YM
Clin Lymphoma Myeloma Leuk; 2019 Dec; 19(12):e636-e648. PubMed ID: 31645307
[TBL] [Abstract][Full Text] [Related]
53. Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia.
Kadia TM; Faderl S; Ravandi F; Jabbour E; Garcia-Manero G; Borthakur G; Ferrajoli A; Konopleva M; Burger J; Huang X; Wang X; Pierce S; Brandt M; Feliu J; Cortes J; Kantarjian H
Cancer; 2015 Jul; 121(14):2375-82. PubMed ID: 25809968
[TBL] [Abstract][Full Text] [Related]
54. Therapeutic decision-making in elderly patients with acute myeloid leukemia: conventional intensive chemotherapy versus hypomethylating agent therapy.
Oh SB; Park SW; Chung JS; Lee WS; Lee HS; Cho SH; Choi YS; Lim SN; Shin HJ;
Ann Hematol; 2017 Nov; 96(11):1801-1809. PubMed ID: 28828639
[TBL] [Abstract][Full Text] [Related]
55. Efficacy of single-agent decitabine in relapsed and refractory acute myeloid leukemia.
Khan N; Hantel A; Knoebel RW; Artz A; Larson RA; Godley LA; Thirman MJ; Liu H; Churpek JE; King D; Odenike O; Stock W
Leuk Lymphoma; 2017 Sep; 58(9):1-7. PubMed ID: 28278716
[TBL] [Abstract][Full Text] [Related]
56. Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia.
Blum W; Klisovic RB; Hackanson B; Liu Z; Liu S; Devine H; Vukosavljevic T; Huynh L; Lozanski G; Kefauver C; Plass C; Devine SM; Heerema NA; Murgo A; Chan KK; Grever MR; Byrd JC; Marcucci G
J Clin Oncol; 2007 Sep; 25(25):3884-91. PubMed ID: 17679729
[TBL] [Abstract][Full Text] [Related]
57. Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study.
Wei AH; Strickland SA; Hou JZ; Fiedler W; Lin TL; Walter RB; Enjeti A; Tiong IS; Savona M; Lee S; Chyla B; Popovic R; Salem AH; Agarwal S; Xu T; Fakouhi KM; Humerickhouse R; Hong WJ; Hayslip J; Roboz GJ
J Clin Oncol; 2019 May; 37(15):1277-1284. PubMed ID: 30892988
[TBL] [Abstract][Full Text] [Related]
58. Clinical Results of Hypomethylating Agents in AML Treatment.
Cruijsen M; Lübbert M; Wijermans P; Huls G
J Clin Med; 2014 Dec; 4(1):1-17. PubMed ID: 26237015
[TBL] [Abstract][Full Text] [Related]
59. Long-term follow-up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias.
de Lima M; Ravandi F; Shahjahan M; Andersson B; Couriel D; Donato M; Khouri I; Gajewski J; van Besien K; Champlin R; Giralt S; Kantarjian H
Cancer; 2003 Mar; 97(5):1242-7. PubMed ID: 12599231
[TBL] [Abstract][Full Text] [Related]
60. Decitabine and all-trans retinoic acid synergistically exhibit cytotoxicity against elderly AML patients via miR-34a/MYCN axis.
Cao Y; Liu Y; Shang L; Wei W; Shen Y; Gu Q; Xie X; Dong W; Lin Y; Yue Y; Wang F; Gu W
Biomed Pharmacother; 2020 May; 125():109878. PubMed ID: 32006898
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]